Nasal drug delivery devices: Characteristics and performance in a clinical perspective-a review

Drug Delivery and Translational Research

Volumn 3, Issue 1, 2013, Pages 42-62

  Djupesland, Per Gisle ^a  

^a OptiNose AS   (Norway)

Author keywords

Clearance; Device; Drug delivery; Nasal; Nasal valve; Paranasal sinuses; Particle deposition; Systemic; Topical; Vaccine

Indexed keywords

APOMORPHINE; BUDESONIDE; CALCITONIN; DECONGESTIVE AGENT; DESMOPRESSIN; DEXAMETHASONE CIPECILATE; FLUTICASONE; FLUTICASONE PROPIONATE; INFLUENZA VACCINE; INSULIN; KETOROLAC; MIDAZOLAM; NOSE DROPS; NOSE SPRAY; OXYTOCIN; PLACEBO; STEROID; SUMATRIPTAN; TRIPTAN DERIVATIVE; VACCINE; ZOLMITRIPTAN;

AEROSOL; ALLERGIC RHINITIS; ALZHEIMER DISEASE; ANATOMICAL CONCEPTS; BIOAVAILABILITY; CATHETER; CHRONIC RHINOSINUSITIS; CLUSTER HEADACHE; COMMON COLD; DIABETES INSIPIDUS; DRUG ABSORPTION; DRUG DEGRADATION; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG METABOLISM; FLUID RETENTION; HUMAN; INHALER; LUNG GAS EXCHANGE; METERED DOSE INHALER; MIGRAINE; NEBULIZER; NOCTURNAL ENURESIS; NOSE AIRFLOW; NOSE AIRWAY RESISTANCE; NOSE CAVITY; NOSE MUCOSA; NOSE POLYP; OSTEOPOROSIS; PAIN; PARANASAL SINUS; PARKINSON DISEASE; PIPETTE; PREDICTIVE VALUE; PRIORITY JOURNAL; PUMP; REVIEW; RHINITIS; SINUSITIS; SMELLING; VACCINATION;

EID: 84875516600     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0108-9     Document Type: Review

References (118)

1. FDA 2003. US FDA draft guidance for industry. Bioavailability and bioequivalence studies for nasal aerosols and nasal sprays. Bethesda. http://www. fda. gov/cder/guidance/index. htm. Accessed July 2012.
2. Suman JD, Laube BL, Dalby R. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition, absorption and biologic response. J Aerosol Med. 2006; 19: 510-21.
3. Vidgren MT, Kublik H. Nasal delivery systems and their effect on deposition and absorption. Adv Drug Deliv Rev. 1998; 29: 157-77.
4. Sahin-Yilmaz A, Naclerio RM. Anatomy and physiology of the upper airway. Proc Am Thorac Soc. 2011; 8: 31-9.
5. Cole P. Nasal respiratory function. In: The nose. St. Louis: Mosby-Year Book Inc.; 1993. p. 3-60.
6. Cole P. The mouth and the throat. In: The nose. St. Louis: Mosby-Year Book Inc.; 1993. p. 61-90.
7. Haight JS, Cole P. The site and function of the nasal valve. Laryngoscope. 1983; 93: 49-55.
8. Yu S, Liu Y, Sun X, Li S. Influence of nasal structure on the distribution of airflow in nasal cavity. Rhinology. 2008; 46: 137-44.
9. Cole P. The four components of the nasal valve. Am J Rhinol. 2003; 17: 107-10.
10. Fodil R, Brugel-Ribere L, Croce C, Sbirlea-Apiou G, Larger C, Papon JC, Delclaux C, Coste A, Isabay D, Louis B. Inspiratory flow in the nose: a model coupling flow and vasoerectile tissue distensibility. J Appl Physiol. 2005; 98: 288-95.
11. Cole P. Nasal and oral airflow resistors. Site, function, and assessment. Arch Otolaryngol Head Neck Surg. 1992; 118: 790-3.
12. Gomes AC, Sampaio-Teixeira ACM, Trindade SHK, Trindade IEK. Nasal cavity geometry of healthy adults assessed using acoustic rhinometry. Rev Bras Otorrinolaringol. 2008; 74(5): 746-54.
13. Djupesland PG, Skretting A, Windern M, Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope. 2006; 116(3): 466-72.
14. Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm. 2012. doi: 10. 1089/jamp. 2011. 0924.
15. Swift DL, Proctor DF. Access of air to the respiratory tract. In: Brain DJ, Proctor DF, Reid LM, editors. Respiratory defense mechanisms. New York: Marcel Dekker; 1977. p. 63-93.
16. Mann DG, Sasaki CT, Fukuda H, Suzuki M, Hernandez JR. Dilator naris muscle. Ann Otol Rhinol Laryngol. 1977; 86: 362-70.
17. Djupesland PG, Skatvedt O, Brogersen AK. Dichotomous physiological effects of nocturnal external nasal dilation in heavy snorers: the answer to a rhinological controversy? Am J Rhninol. 2001; 15(2): 95-103.
18. Hairfield WM, Warren DW, Hinton VA, Seaton DL. Inspiratory and expiratory effects of nasal breathing. Cleft Palate J. 1987; 24: 183-9.
19. Mygind N, Dahl R. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev. 1998; 29: 3-12.
20. Proctor DF. The mucociliary system. In: Proctor DF, Andersen I, editors. The nose: upper airway physiology and the atmospheric environment. Amsterdam: Elsevier Biomedical; 1982. p. 245-78.
21. Halama AR, Decreton S, Bijloos JM, Clement PAR. Density of epithelial cells in the normal human nose. A scanning electron microscopic study. Rhinology. 1990; 28: 25-32.
22. Svensson S, Olin AC, Hellgren J. Increased net water loss by oral compared to nasal expiration in healthy subjects. Rhinology. 2006; 44: 74-7.
23. Andersen I, Lundqvist GR, Jensen PL, Proctor DF. Human response to controlled levels of sulfur dioxide. Arch Environ Hlth. 1974; 28: 31-9.
24. Brandtzaeg P. Role of secretory antibodies in the defense against infections. Int J Med Microbiol. 2003; 293: 1-13.
25. Baraniuk JN. Neural regulation of mucosal function. Pulm Pharmacol Ther. 2008; 21(3): 442-8.
26. Cole P. Stability of nasal airflow. Clnin Otolaryngol. 1989; 14: 177-82.
27. Cole P, Haight JSJ. Posture and the nasal cycle. Ann Otol Rhinol Laryngol. 1986; 95: 223-7.
28. Havas TE, Cole P, Gullane PJ, et al. The nasal cycle after laryngoectomy. Acta Otolaryngo (Stockh). 1987; 103: 111-6.
29. Djupesland PG, Chatkin JM, Qian W, Haight JSJ. Nitric oxide in the nasal airway: a new dimension in otolaryngology. Am J Otolaryngol. 2001; 22: 19-32.
30. Qian W, Sabo R, Ohm M, Haight JSJ, Fenton R. Nasal nitric oxide and the nasal cycle. Laryngoscope. 2001; 111: 1603-7.
31. Jones N. The nose and paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev. 2001; 51: 5-19.
32. Einer-Jensen N, Larsen L. Local transfer of diazepam, but not of cocaine, from the nasal cavities to the brain arterial blood in rats. Pharmacol Toxicol. 2000; 87: 276-8.
33. Einer-Jensen N, Larsen L, Deprez S, Starns E, Schwartz S. Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. Biopharm Drug Dispos. 2001; 22(5): 213-9.
34. Dhuria S, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2009. doi: 10. 1002/jps. 21924.
35. Landis BN, Scheibe M, Weber C, Berger R, Brämerson A, Bende M, Nordin S, Hummel T. Chemosensory interaction: acquired olfactory impairment is associated with decreased taste function. J Neurol. 2010; 257: 1303-8.
36. Brant JG. Within reach of an end to unnecessary bitterness. Lancet. 2000; 356: 1371-2.
37. Feron F, Perry C, McGrath JJ, Mackay-Sim A. New techniques for biopsy and culture of human olfactory epithelial neurons. Arch Otolaryngol Head Neck Surg. 1988; 124(8): 861-6.
38. Leopold DA, Hummel T, Schwob JE. Anterior distribution of human olfactory epithelium. Laryngoscope. 2000; 110: 417-21.
39. Hummel T, Livermore A. Intranasal chemosensory function of the trigeminal nerve and aspects of its relation to olfaction. Int Arch Occup Environ Health. 2002; 75: 305-13.
40. Husner A, Frasnelli J, Welge-Lussen A, Reiss G, Zahnert T, Hummel T. Loss of trigeminal sensitivity reduces olfactory function. Laryngoscope. 2006; 116: 1520-2.
41. Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid spary in the treatment of rhinitis: is one better than another? J Laryngol Otol. 2003; 117: 8843-5.
42. Laube B. Devices for aerosol delivery to treat sinusitis. J Aerosol Med. 2007; 20(Suppl): 5-18.
43. Aggrawal R, Cardozo A, Homer JJ. The assessment of topical nasal drug distribution. Clin Otolaryngol. 2004; 29: 201-5.
44. Johnson HJ, Hanson LR, Frey WH. Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures. Mol Pharm. 2010; 7(3): 884-93.
45. Marple B, Roland P, Benninger M. Safety review of benzalkonium chloride used as a preservative in intranasal solutions: an overview of conflicting data and opinions. Otolaryngol Head Neck Surg. 2004; 130: 131-41.
46. Illum L. Nasal drug delivery: possibilities, problems and solutions. J Control Release. 2003; 87: 187-98.
47. Penttilä M, Poulsen P, Hollingworth K, Holmström M. Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy. 2000; 30: 94-102.
48. Keith P, Nieminen J, Hollingworth K, Dolovich J. Efficacy and tolerability of fluticasone propionate nasal drops 400 μg once daily compared with placebo for the treatment of bilateral polyposis in adults. Clin Exp Allergy. 2000; 30: 1460-8.
49. Merkus P, Ebbens FA, Muller B, Fokkens WJ. Influence of anatomy and head position on intranasal drug deposition. Eur Arch Otorhinolaryngol. 2006; 263: 827-32.
50. Bakke B, Samdal HH, Holst J, et al. Vaccine oral spray immunization may be an alternative to intranasal vaccine delivery to induce systemic antibodies but not nasal mucosal or cellular immunity. Scan J of Immunol. 2006; 63: 223-31.
51. Harris AS, Nilsson IM, Wagner ZG, Alkner U. Intranasal administration of peptides: nasal deposition, biological response and absorption of desmopressin. J Pharm Sci. 1986; 75: 1085-8.
52. Berger WE, Godfrey JW, Slater AL. Intranasal corticosteroids: the development of a drug delivery device for fluticasone furoate as a potential step toward improved compliance. Expert Opin Drug Deliv. 2007; 4(6): 689-701.
53. Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008; 139: 131-6.
54. Renteria SS, Clemens CC, Croyle MA. *Development of a nasal adenovirus-based vaccine: effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices. Vaccine. 2010; 28: 2137-48.
55. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 1999; 282: 137-44.
56. Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med. 2007; 356: 685-96.
57. Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med. 2004; 350: 896-903.
58. Wermeling DP, Miller JL, Archer SM, Rayens MK, Rudy AC. Pharmacokinetics, bioequivalence, and spray weight reproducibility of intranasal butorphanol after administration with 2 different nasal spray pumps. J Clin Pharmacol. 2005; 45: 969-73.
59. Rapoport A, Winner P. Nasal delivery of antimigraine drugs: clinical rationale and evidence base. Headache. 2006; 46 Suppl 4: S192-201.
60. Hankin CS, Cox L, Lang D, Bronstone, Wang Z, Lepore MS, Buck PO. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. All Asthma Proc. 2012; 33: 258-64.
61. Mygind N, Vesterhauge S. Aerosol distribution in the nose. Rhinology. 1978; 16: 79-88.
62. Meltzer EO, Jacobs RL, LaForce CF, Kelley CL, Dunbar SA, Tantry SK. Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis. Asthma Proc. 2012; 33: 249-57.
63. Newman SP, Moren F, Clarke SW. The nasal distribution of metered dose inhalers. J Laryngol Otol. 1987; 101: 127-32.
64. Inthavong K, Tian ZF, Tu JY, Yang W, Xue C. Optimising nasal spray parameters for efficient drug delivery using computational fluid dynamics. Computers in Biol Med. 2008; 38: 713-26.
65. Kundoor V, Dalby RN. Effect of formulation- and administration-related variables on deposition pattern of nasal spray pumps evaluated using a nasal cast. Pharm Res. 2011; 28: 1895-904.
66. Suman J, Laube BL, Dalby R. Comparisonof nasal deposition and clearance of aerosol generated by nebulizer and aqueous spray pump. Pharm Res. 1999; 16: 1648-52.
67. Vaughan WC, Carvalho G. Use of nebulized antibiotics for acute infections in chronic sinusitis. Otolaryngol Head Neck Surg. 2002; 127: 558-68.
68. Möller W, Saba GK, Häussinger K, Becker S, Keller M, Schuschnig U. Nasally inhaled pulsating aerosols: lung, sinus and nose deposition. Rhinology. 2011; 49: 286-91.
69. Djupesland PG, Skretting A, Windern M, Holand T. A novel concept for nasal delivery of aerosols can prevent lung inhalation. J Aerosol Med. 2004; 17(3): 249-59.
70. Skretting A, Djupesland PG. A new method for scintigraphic quantification of deposition and clearance in anatomical regions of the human nose. Nucl Med Comm. 2009; 30(8): 629-38.
71. Djupesland PG, Craft S. Intranasal insulin improves cognition and modulates β-amyloid in early AD. Letters to the editor. Neurology. 2008; 71: 864.
72. Vecellio L, De Gersem R, Le Guellec S, et al. Deposition of aerosols delivered by nasal route with jet and mesh nebulizers. Int J Pharm. 2011; 407: 87-94.
73. Giroux M. Controlled particle dispersion: effective nasal delivery from a versatile, flexible delivery platform. OndrugDelivery. www. ondrugdelivery. com. 2005; 13-15.
74. Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology. 2008; 70(6): 440-8.
75. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol. 2012; 69(1): 29-38.
76. Selam J. Inhaled insulin: promises and concerns. J Diabetes Sci Technol. 2008; 2(2): 311-5.
77. Hoekman JD, Ho RJY. Enhanced analgesic responses after preferential delivery of morphine and fentanyl to the olfactory epithelium in rats. Anesth Analg. 2011; 113: 641-51.
78. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharma. 1999; 178: 55-65.
79. Thorsson L, Newman SP, Weisz A, Trofast E, Moren F. Nasal distribution of budesonide inhaled via a powder inhaler. Rhinology. 1993; 31: 7-10.
80. Tos M, Svendstrup F, Arndal H, et al. Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol. 1998; 12: 183-9.
81. Cho HJ, Balakrishnan P, Shim WS, Chung SJ, Shim CK, Kim DD. Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron-cyclodextrin complex and carboxymethylcellulose for intranasal delivery. Int J Pharm. 2010; 400(1-2): 59-65.
82. Haruta S, Tsutsui T. Meeting the needs for nasal delivery devices for powder formulations. Drug Dev Deliv. 2012; 12(5): 22-7.
83. Kaye RS, Purewal TS, Alpar OH. Development and testing of particulate formulations for the nasal delivery of antibodies. J Control Rel. 2009; 135: 127-35.
84. Pringels E, Callens C, Vervaet C, Dumont F, Slegers G, Foreman P, Remona JP. Influence of deposition and spray pattern of nasal powders on insulin bioavailability. Int J Pharma. 2006; 310: 1-7.
85. Huanga J, Garmise RJ, Crowder TM, Mara K, Hwanga CR, Hickey AJ, Mikszta JA, Sullivana VJ. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine. 2004; 23: 794-801.
86. Keldmann E. Patent application. Inhaler for powdered medicament. WO 98/53869. 1998.
87. Vlckova I, Navrátil P, Kaňa R, et al. Effective treatment of mild-to-moderate nasal polyposis with fluticasone delivered by a novel device. Rhinology. 2009; 47: 419-26.
88. Hansen F, Djupesland PG, Fokkens WJ. Effective treatment of chronic rhinosinusitis with fluticasone delivered by a novel device: a randomized placebo controlled pilot study. Rhinology. 2010; 48: 292-9.
89. Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryltrinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009; 61: 1219-28.
90. Djupesland PG, Dočekal P. Intranasal sumatriptan powder delivered by a novel breath actuated Bi-Directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia. 2010. doi: 10. 1177/0333102409359314.
91. Dale O, Nilsen T, Loftsson T, Tønnesen HH, et al. Intranasal midazolam: a comparison of two delivery devices in human volunteers. J Pharma Pharmacol. 2006; 58: 1311-8.
92. Fox AW. Onset of effect of 5-HT1B/1D agonists: a model with pharmacokinetic validation. Headache. 2004; 44: 142-7.
93. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of, sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci. 1998; 6: 99-104.
94. Djupesland PG, Mahmoud R, Messina J, Miller P. Rate of systemic absorption of sumatriptan may not explain differences in headache response suggesting the potential for an additional route to the site of action. Cephalalgia. 2011; 31 Suppl 1: PS1-PS55.
95. Djupesland PG, Vlckova I, Hewson G. Impact of baseline nasal polyp size and previous surgery on efficacy of fluticasone delivered with a novel device: a subgroup analysis. A J Rhinol Allergy. 2010. doi: 10. 2500/ajra. 2010. 24. 3516.
96. Fokkens WJ. Unmet needs in rhinology. Rhinology. 2008; 46: 257-8.
97. Fokkens WJ. Recalcitrant rhinosinusitis, the diagnosis and treatment and evaluation of results. Rhinology. 2010; 48: 257-8.
98. Kleven M, Djupesland PG, Melaaen M. Computational fluid dynamics (CFD) applied on the drug delivery design process to the nasal passages: a review. J Mech Med Biol. 2012. doi: 10. 1142/S0219519411004526.
99. Frank DO, Kimbell JS, Pawar S, Rhee JS. Effects of anatomy and particle size on nasal sprays and nebulizers. Oto Head Neck Surg. 2012; 146(2): 313-9.
100. Inthavong K, Ge Q, Se CMK, Yang W, Tu JY. Simulation of sprayed particle deposition in a human nasal cavity including a nasal spray device. J Aerosol Sci. 2011; 42: 100-13.
101. Sommer F, Kröger R, Lindemann J. Numerical simulation of humidification and heating during inspiration within an adult nose. Rhinology. 2012. doi: 10. 4193/Rhino. 11. 231.
102. Kleven M. Numerical simulations and experimental studies for nasal delivery of vaccines and drugs. Thesis. NTNU. 2012. ISBN: 978-82-471-3398-9.
103. Guo Y, Laube B, Dalby R. The effect of formulation variables and breathing patterns on the site of nasal deposition in an anatomically correct model. Pharm Res. 2005; 22(11): 1871-8.
104. Kundoor V, Dalby RN. Assessment of nasal spray deposition in a silicone human nose model using a color based method. Pharm Res. 2010; 27(1): 30-6.
105. Djupesland PG. A critical view on the use of nasal casts to assess nasal spray deposition patterns. ARS 2012. Poster #P-2. http://www. american-rhinologic. org/previous_meeting.
106. Rudman KL, O'Brien EK, Leopold DA. Radiographic distribution of drops and sprays within the sinonasal cavities. Am J Rhinol Allergy. 2011; 25: 94-7.
107. Benninger MS, Hadley JA, Osguthorpe JD, Marple BF, Leopold DA, Derebery MJ, et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg. 2004; 130: 5-24.
108. Merkus P, Ebbens FA, Muller B, Fokkens WJ. The 'best method' of topical nasal drug delivery: comparison of seven techniques. Rhinology. 2006; 44: 102-7.
109. Al-Ghananeem AM, Sandefer EP, Doll WJ, Page RC, Chang Y, Digenis GA. Gamma scintigraphy for testing bioequivalence: a case study on two cromolyn sodium nasal spray preparations. Int J Pharm. 2008; 357: 70-6.
110. McInnes FJ, O'Mahony B, Lindsay B, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci. 2007; 31: 25-31.
111. Newman SP, Moren F, Clarke SW. Deposition pattern of nasal sprays in man. Rhinology. 1987; 26: 111-20.
112. Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm. 2012; 25(3): 140-7.
113. McLean JA, Bacon JR, Mathews KP, Thrall JH, Banas JM, Hedden J, Bayne NK. Deposition and clearance of mucoradioactive aerosol on the nasal mucosa. Rhinology. 1984; 22: 65-75.
114. Harris AS, Ohlin M, Lethagen S, Nilsson IM. Effect of concentration and volume on nasal bioavailability and biological response to desmopressin. J Pharm Sci. 1988; 77: 337-9.
115. Costantino HR, Illum L, Brandt G, Johnson PH, Quaya SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharma. 2007; 337: 1-24.
116. Bond W, Hardy JG, Wilson CG. Deposition and clearance of nasal sprays. In: Aiache JM, Hirtz J, editors. Proceedings volume I, Biopharmaceutics; 1985. pp. 93-8.
117. Hardy JG, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol. 1985; 37: 294-7.
118. Righton L. Bringing the patient's voice to nasal drug delivery. ONdrugDelivery. www. ondrugdelivery. com. 2011; 4-7.